| 353344 | Q6VZZ7 | OPN5_MOUSE | Opsin-5 (G-protein coupled receptor 136) (G-protein coupled receptor PGR12) (Neuropsin) | DISRUPTION PHENOTYPE | Ultrastructure of the retina is normal (PubMed:30936473, PubMed:30240620, PubMed:26392540). Newborn mice show normal hyaloid vessel numbers and normal vessel cellularity (PubMed:30936473). Retinas show normal expression patterns of rod and cone opsins including Opn4 (PubMed:26392540, PubMed:30240620). Decreased activated Vegfr2 in the hyaloid vessels and increased activated Akt1 at P5 (PubMed:30936473). Reduced levels of dopamine in the retina, however increased levels in the vitreous at P6 (PubMed:30936473). Reduced number of hyaloid blood vessels due to precocious regression, however no change in abundance of Vegfa or Flt1 at P8 (PubMed:30936473). Expression of tyrosine hydroxylase Th in retinal cell processes at P8, with increased expression in developed dopaminergic amacrine cells at P15 (PubMed:30936473). Loss of retinal and corneal circadian rhythm photoentrainment (PubMed:26392540, PubMed:30240620). Reduced UVA-induced phase-shift response and Fos expression in the suprachiasmatic nuclei (SCN) in the brain (PubMed:30240620). Abolishes retinaldehyde-dependent photoentrainment in the dermal tissues of the outer ear and vibrissal pad (PubMed:31607531). Loss of phase shifting activity in response to violet light and expression of circadian clock-genes in the skin of the outer ear during light-to-dark cycle, including Per1, Per2, Cry2, Dbp and Nr1d2 (PubMed:31607531). Pde6b and Opn5 double knockout mice also show loss of retinal ultrastructures and a more severe reduction in the rate of circadian photoentrainment, light-induced phase-shift response and Fos expression in the SCN (PubMed:30240620). {ECO:0000269|PubMed:26392540, ECO:0000269|PubMed:30240620, ECO:0000269|PubMed:30936473, ECO:0000269|PubMed:31607531}. |